Egg Allergy
16
5
5
7
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 37/100
0.0%
0 terminated out of 16 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
43%
3 of 7 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 7 completed trials
Clinical Trials (16)
Comparison Between a Rush and a Conventional Oral Immunotherapy Protocol to Treat Cow's Milk and Hen´s Egg Allergy. CompITO Study
Investigating Modified Protocols of Oral Immunotherapy to Validate Efficacy and Safety
A Long Term, Observational Follow-Up Study of Children and Young People Who Underwent an 18-Month Course of Oral Immunotherapy Treatment for Peanut, Egg or Milk Allergy (5-15 Years Post-Treatment)
Pancake Oral Immunotherapy For Egg Allergy In Inducing Tolerance
Expecting Mother's Study of Consumption or Avoidance of Peanut and Egg
Efficacy and Safety of Egg Ladders in Children With IgE-Mediated Hen's Egg Protein Allergy
Oral Immunotherapy for Egg Allergy in Children Aged 6 to 16
The Clinical Impact of the Basophil Activation Test to Diagnose Food Allergy
The Utility of Food-Specific IgE Measured With the IMMULITE 2000 Assay to Predict Symptomatic Food Allergy
Basophil Activation Test to Diagnose Food Allergy
Promoting Tolerance to Peanut in High-Risk Children
FluMist in Egg Allergic Patients
Safe Administration of Flu Vaccine to Egg Allergic Children
Persistence of Oral Tolerance to Peanut
Cow's Milk and Hen's Egg Hyposensitization in Adults
Clinical Tolerance to a Live Attenuated Vaccine Against Influenza (Flumist®) in a Population Allergic to Eggs